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To our knowledge, we are reporting the ﬁrst case of a 59-year-old man who developed recurrent CME with three separate trials of
threediﬀerentprostaglandinclassdrugsfollowinguncomplicatedphacoemulsiﬁcationwithintraocularlensimplantation.Despite
multiple reports of individual prostaglandin (PG) analogues being suggested as the cause of CME, there are no recommendations
regarding withholding these medications in the perioperative period. Our patient ﬁrst developed CME OD 4-months post
uncomplicated cataract extraction. XALATAN (Latanoprost) had been restarted after surgery and discontinued at onset of
CME. While oﬀ XALATAN (Latanoprost), the patient’s CME resolved, but his IOP rose. The patient was started on LUMIGAN
(Bimatoprost) to control the IOP, but within weeks his CME recurred. The patient’s CME was again treated and his IOP remained
acceptable,butthenprogressivelyincreased.TRAVATAN(Travoprost)wasattempted,buthepresentedwithathirdroundofCME.




s u r g e r i e sf o rc a t a r a c t se a c hy e a ri nt h eU . S .Ac o m m o nc l i n -
ical scenario in a percentage of patients undergoing cataract
extractionisreceivingtreatmentforco-morbiditieslikeglau-
coma with hypotensive lipids. We report a case of a 59-year-
old man who developed recurrent cystoid macular edema
(CME) with three separate trials of prostaglandin analogs
following uncomplicated phacoemulsiﬁcation with intraoc-
ular lens implantation. Currently, we have no prospective,
blinded-control trials to better deﬁne the ideal perioperative
strategies in this patient population.
2.CaseReport
Our patient has a history of advanced pigmentary glau-
coma in both eyes, which was controlled preoperatively for
many years with XALATAN (Latanoprost), COSOPT (Timo-
lol/Dorzolamide) ﬁxed combination, and ALPHAGAN (Bri-
monidine) 0.1% purite OU. The patient developed visually
signiﬁcant cataracts in both eyes with visual acuity dropping
below 20/40 OU prior to surgery. He had uncomplicated
cataract extraction with IOL implant OD, followed one
month later by OS. His best corrected visual acuity in each
eye was 20/20 OU by one week post op. His immediate
post-op regimen was AVELOX (Moxiﬂoxacin) QID for one
week, diclofenac QID for one month, and PRED FORTE
(prednisolone) 1% QID for one week and then tapered oﬀ
over the next three weeks. His XALATAN (Latanoprost) was
resumed immediately post-op.
Our patient ﬁrst developed CME in his right eye 4-
months post-cataract extraction, when he presented with
complaints of blurry vision and central distortion. A dilated
fundus exam revealed cystoid macula edema, conﬁrmed
by OTC. The BCVA had dropped from 20/20 to 20/70.
XALATAN (Latanoprost) was discontinued, and diclofenac
was initiated. After 1-month, his BCVA and intraocular
pressure OD were 20/70 and 16mm Hg, respectively. Over
the next two months while oﬀ the XALATAN (Latanoprost),
the patient’s CME improved, and visual acuity improved to
20/30 +2, but intraocular pressure climbed to 28mmHg.2 Journal of Ophthalmology
Within three weeks of initiating LUMIGAN (Bimatoprost)
in an eﬀort to control his increased IOP his CME symptoms
recurred for a second time, and his BCVA dropped again
to 20/60. The patient’s CME was again re-treated with a
combination of topical diclofenac QID, and PRED FORTE
(prednisolone) 1% QID. Prostaglandin therapy was avoided
for a period of 13-months. His BCVA after resolution of the
second episode of CME was 20/25 and remained stable for
13 months.
For one year after the second episode of CME, the
IOP remained in the borderline acceptable range on
ALPHAGAN (Brimonidine) 0.1% purite and COSOPT
(Timolol/Dorzolamide) ﬁxed combination OU. He became
progressively worse when he presented with an IOP of
28mmHg, at which time a trial of TRAVATAN (Travoprost)
was attempted. Within 3-weeks the patient presented with
third round of CME in the right eye. TRAVATAN (Travo-
prost) was the third prostaglandin therapy to date that
seems to have triggered CME in our pseudophakic patient
and was again discontinued. The patient’s third episode of
CME eventually resolved with the prior treatments, and his
BCVA stabilized at 20/25. His IOP at the time of this report
is controlled with COSOPT (Timolol/Dorzolamide) ﬁxed
combination and ALPHAGAN (Brimonidine) 0.1% purite.
3. Discussion
CME is a painless condition in which swelling or thickening
occursofthecentralretina(macula)andisusuallyassociated
with blurred or distorted vision. The primary cause of CME
depends on the underlying disease process, but most path-
ways eventually lead to vascular instability and breakdown
of the blood-retinal barrier. The M¨ uller cells in the retina
become overwhelmed with ﬂuid leading to their lysis. This
resultsinanaccumulationofﬂuidintheouterplexiformand
inner nuclear layers of the retina [1].
Endogenous prostaglandins (PGs) are known to modu-
late normal cell function as well as inﬂammatory response.
The conventional route of aqueous humor ﬂow is through
the trabecular meshwork, Schlemm’s canal and episcleral
vessels. It is thought that PGs may regulate uveoscleral
outﬂow by metalloproteinases- (MMP)-mediated alterations
in the ciliary muscle in extracellular matrix metabolism [2–
4]. It has also been shown that XALATAN (Latanoprost)
induces cystoid macular edema (CME) in patients in the
early postoperative period of cataract surgery as well as
numerous case reports documenting CME with XALATAN
(Latanoprost) use [5–7]. Halpern and Pasquale documents
thirty-four eyes of thirty-two patients with documented
CME in aphakia and pseudophakia [8].
Structurally, XALATAN (Latanoprost), TRAVATAN
(Travoprost), and LUMIGAN (Bimatoprost) are all com-
pounds related to prostaglandin 2α. Both XALATAN
(Latanoprost) and TRAVATAN (Travoprost) are pharmaco-
logically classiﬁed as prostaglandin analogs, but LUMIGAN
(Bimatoprost) is considered to be a prostamide because it
is an amide rather than an ester compound [9]. XALATAN
(Latanoprost) is an isopropyl ester prodrug of 17-phenyl
substituted prostaglandin F2α that eﬀectively lowers IOP
by enhancing uveoscleral outﬂow without signiﬁcantly
aﬀecting other parameters of aqueous humor dynamics [10].
All drugs showed increased uveoscleral outﬂow, although
the amount varied among the techniques [11].
However, the association between ocular hypotensive
lipids and cystoid macula edema continues to be subject
of debate. It has been suggested that it is unlikely topical
XALATAN (Latanoprost) induces cystoid macula edema in
eyes with a normally functioning blood-ocular barrier [5].
Interestingly, our patient, who had been uneventfully treated
with XALATAN (Latanoprost) for several years, developed
cystoid macular edema that worsened with rechallenge of
LUMIGAN (Bimatoprost) and TRAVATAN (Travoprost),
even more than one year after uncomplicated anterior
segment surgery. Cystoid macular edema associated with
XALATAN (Latanoprost) has been reported after uncompli-
cated cataract surgery, but it is an uncommon complication.
In one retrospective review of a cohort of patients after
uneventful phacoemulsiﬁcation, 3% developed clinically
signiﬁcant CME [12]. It has also been associated with
LUMIGAN (Bimatoprost) in an eye with high-risk proﬁle.
To our knowledge, this case represents the only report in the
literature that deﬁnitively identiﬁes prostaglandin analogs as
the inciting agent in recurrent CME.
Optical coherence tomography (OCT) is helpful in
establishing a diagnosis and in measuring the therapeutic
response. Classically, patients with CME demonstrate retinal
thickening and cystic spaces on OTC. Medical treatment
modalities include corticosteroids, which directly inhibit
the enzyme phospholipase, blocking the formation of
prostaglandins. They are considered the primary treatment
of CME in many instances, speciﬁcally in the treatment
of CME secondary to uveitis. However, corticosteroids
have many systemic and ocular adverse eﬀects, and some
patients become intolerant to them as a result. NSAIDs, like
Diclofenac (Voltaren), inhibit the enzyme cyclooxygenase
and can be used in the prevention and treatment of CME.
NSAIDs are sually administered topically for approximately
3-4 months and on an asneededbasis. In a prospective,
double-masked, study of indomethacin versus placebo in
the treatment of patients undergoing cataract extraction the
incidence of angiographic CME was higher in the placebo
treated group [13]. In addition, treatment of CME with
steroid and NSAIDs has been shown to be better than
NSAIDs alone [14].
Despite multiple case reports of individual prostaglandin
analogues being suggested as the cause of CME, there
is currently no consensus or recommendation regarding
the use of these medications in the perioperative period.
Remissions and exacerbations of macular edema can result
in photoreceptor damage with permanent impairment of
vision. Deﬁnitive conclusions about causal relationships
cannot be made without well-designed, prospective clinical
trials addressing this issue given the large number of patients
undergoing cataract extraction every year in the U.S. while
being treated for glaucoma. More research in this area is
important to understand if a causal relationship between the
use of PG analogs and the occurrence of CME is more than
anecdotal associations in the case reports. Caution might beJournal of Ophthalmology 3
advised when using PG analogs in eyes with risk factors for
the development of CME.
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